Cardiac energy metabolism alterations in angiotensin II induced hypertrophy

Journal of Molecular and Cellular Cardiology

Volumn 41, Issue 3, 2006, Pages 418-420

  Lopaschuk, Gary D ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; CARBOHYDRATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; GLUCOSE; LACTIC ACID; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

EDITORIAL; ENERGY METABOLISM; FATTY ACID OXIDATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE METABOLISM; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN II; ANIMALS; DISEASE PROGRESSION; ENERGY METABOLISM; FATTY ACIDS; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTROPHY; MICE; MODELS, BIOLOGICAL; MYOCARDIUM; OXYGEN;

EID: 33748414468     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.06.005     Document Type: Editorial

References (11)

1. Serneri G.G., Boddi M., Cecioni I., Vanni S., Coppo M., Pap M.L., et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ. Res. 88 (2001) 961-968
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325 (1991) 293-302
3. Bristow M.R., Gilbert E.M., Abraham W.T., Adams K.F., Fowler M.B., Hershberger R.E., et al. Cardvediol produces dose-related improvements in left ventricular functions and survival in subjects with chronic heart failure. MOCHA Invest. Circ. 94 (1996) 2807-2816
4. Stanley W., Recchia F.A., and Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85 (2005) 1093-1129
5. Sack M.N., Disch D.L., Rockman H.A., and Kelly D.P. A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophihc growth program. PNAS U. S. A. 94 (1997) 6438-6443
6. Young M.E., Laws F.A., Goodwin G.W., and Taegtmeyer H. Reactivation of peroxisome proliferators-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J. Biol. Chem. 276 (2001) 44390-44395
7. Ingwall J.S., and Weiss R.G. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ. Res. 37 (2004) 613-623
8. Lee L., Campbell R., Scheuermann-Freestone M., Taylor R., Gunaruwan P., Williams L., et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 112 (2005) 3280-3288
9. Rupp H., Zarain-Herzberg A., and Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz 27 (2002) 621-636
10. Fragasso G., Piatti P.M., Monti L., Palloshi A., Seola E., Puccetti P., et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am. Heart J. 146 (2003) E18-E24
11. Sabbah H.N., Chandler M.F., Mishima T., Suzuki G., Chaudhry P., Nass O., et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor improves left ventricular function in dogs with chronic heart failure. J. Card Fail 8 (2002) 416-422